Back in June 2019, the European generics and biosimilars industry was celebrating the imminent arrival of the supplementary protection certificate (SPC) manufacturing waiver. The mechanism had been long-sought by the off-patent industry, and promised to allow European manufacturers to compete on an equal footing with non-EU competitors by permitting manufacturing for export outside the EU, as well as stockpiling for day-one launch within the EU, during the term of SPCs (see sidebar).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?